2.80 USD
↗ 0.10 (3.70%)LIVE (AS OF 03:22 PM EDT)
Kalaris Therapeutics, Inc. Common Stock
KLRSNASDAQ • USD
Market: OPEN
Kalaris Therapeutics, Inc. Common Stock (KLRS) trades at $2.80 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Oct 2, 2026.
Open?$2.72
High?$2.83
Low?$2.64
Prev. Close?$2.70
Volume?14.2K
Avg. Volume?70.7K
VWAP?$2.74
Rel. Volume?0.20x
Bid / Ask
Bid?$2.35 × 100
Ask?$2.78 × 100
Spread?$0.43
Midpoint?$2.57
Valuation & Ratios
Market Cap?64.3M
Shares Out?23.8M
Float?5.6M
Float %?23.7%
P/E Ratio?N/A
P/B Ratio?1.11
EPS?-$1.86
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Employees
20
Market Cap
64.3M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2025-03-19
Address
400 CONNELL DRIVE
BERKELEY HEIGHTS, NJ 07922
Phone: 650-249-2727
BERKELEY HEIGHTS, NJ 07922
Phone: 650-249-2727
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?54
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.18Distress
Confidence?46%Low
Short InterestHigh
Short % of Float?5.65%Elevated
Short Interest?318.4K
Days to Cover?5.2
Free Float5.6M
Avg Daily Volume60.9K
Settlement Date2026-09-15
Financial Health
Current Ratio?10.98Strong
Quick Ratio?10.98Strong
Cash Ratio?4.94Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.11CHEAP▾
Peers100
S&P95
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.4CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-76.8%WEAK▾
S&P3
ROA?-44.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-41217000
Enterprise Value?$21.1M
Fundamentals ratios updated end of day